Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) EBITDA Margin (2018 - 2025)

Catalyst Pharmaceuticals' EBITDA Margin history spans 11 years, with the latest figure at 34.53% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 496.0% year-over-year to 34.53%; the TTM value through Dec 2025 reached 36.38%, up 304.0%, while the annual FY2025 figure was 36.38%, 304.0% up from the prior year.
  • EBITDA Margin reached 34.53% in Q4 2025 per CPRX's latest filing, down from 35.55% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 41.91% in Q4 2022 to a low of 29.96% in Q3 2023.
  • Average EBITDA Margin over 5 years is 30.75%, with a median of 34.31% recorded in 2024.
  • Peak YoY movement for EBITDA Margin: plummeted -11916bps in 2021, then soared 6406bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 24.08% in 2021, then skyrocketed by 74bps to 41.91% in 2022, then decreased by -25bps to 31.51% in 2023, then rose by 25bps to 39.49% in 2024, then decreased by -13bps to 34.53% in 2025.
  • Per Business Quant, the three most recent readings for CPRX's EBITDA Margin are 34.53% (Q4 2025), 35.55% (Q3 2025), and 35.59% (Q2 2025).